Abstract
Paclitaxel (taxol, 1a) and docetaxel (taxotere, 1b) have established themselves as an important class of antitumor drugs currently available to the oncologist. While the great contribution of these drugs to the management of the disease and their effect on the improvement of the patient quality of life could not be overemphasized, a great deal of research has been ongoing to improve two key pharmacologic factors, antitumor activity and systemic toxicity. Both physical and chemical means have been employed towards the enhancement of antitumor activity and at the same time, lowering the inherent toxicity and side effects of these drugs. This mini-review compiles the recent reported works on the design and development of taxane delivery systems through tumor cell surface receptortargeted delivery mechanisms such as small-molecule peptides and monoclonal antibodies, as well as those on non-targeted procedures such as liposomes, nanostructures, and natural and synthetic polymers.
Keywords: Taxanes, drug delivery, cancer, chemotherapy, prodrugs
Current Drug Delivery
Title: Recent Developments in Taxane Drug Delivery
Volume: 5 Issue: 1
Author(s): Ahmad Safavy
Affiliation:
Keywords: Taxanes, drug delivery, cancer, chemotherapy, prodrugs
Abstract: Paclitaxel (taxol, 1a) and docetaxel (taxotere, 1b) have established themselves as an important class of antitumor drugs currently available to the oncologist. While the great contribution of these drugs to the management of the disease and their effect on the improvement of the patient quality of life could not be overemphasized, a great deal of research has been ongoing to improve two key pharmacologic factors, antitumor activity and systemic toxicity. Both physical and chemical means have been employed towards the enhancement of antitumor activity and at the same time, lowering the inherent toxicity and side effects of these drugs. This mini-review compiles the recent reported works on the design and development of taxane delivery systems through tumor cell surface receptortargeted delivery mechanisms such as small-molecule peptides and monoclonal antibodies, as well as those on non-targeted procedures such as liposomes, nanostructures, and natural and synthetic polymers.
Export Options
About this article
Cite this article as:
Safavy Ahmad, Recent Developments in Taxane Drug Delivery, Current Drug Delivery 2008; 5 (1) . https://dx.doi.org/10.2174/156720108783331005
DOI https://dx.doi.org/10.2174/156720108783331005 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metal-N-Heterocyclic Carbene Complexes as Anti-Tumor Agents
Current Medicinal Chemistry Membrane Domains and the “Lipid Raft” Concept
Current Medicinal Chemistry Cellular Redox Modulator, ortho Mn(III) meso-tetrakis(N-n-Hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP5+ in the Treatment of Brain Tumors
Anti-Cancer Agents in Medicinal Chemistry Hybrid PET/MRI for In Vivo Imaging of Cancer: Current Clinical Experiences and Recent Advances
Current Medical Imaging The Role of CXC-Chemokine IL-8, IL-6 and CXCR2 Receptor in Lymphoplasmacytic Lymphoma: Correlations with Microvascular Characteristics and Clinical Features
Current Angiogenesis (Discontinued) Alkylphospholipids are Signal Transduction Modulators with Potential for Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Exosomes: A Promising Factor Involved in Cancer Hypoxic Microenvironments
Current Medicinal Chemistry New Strategy Developments in Brain Tumor Therapy
Current Pharmaceutical Design Novel Agents Targeting Crucial Signalling Pathways in Head and Neck Squamous Cell Carcinoma, HNSCC - Preclinical Development and Data from Clinical Trials
Current Proteomics The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease
CNS & Neurological Disorders - Drug Targets CDK-associated Cullin 1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Human Glioblastoma
Current Cancer Drug Targets Suicide Gene Therapy Against Malignant Gliomas by the Local Delivery of Genetically Engineered Umbilical Cord Mesenchymal Stem Cells as Cellular Vehicles
Current Gene Therapy Low Concentration of Salinomycin Prevents Regrowth and Partially Depletes Human Glioma Cells Surviving High Concentrations of Alkylating Agents
Clinical Cancer Drugs Reduced Nicotinamide Adenine Dinucleotide (NADH) Fluorescence for the Detection of Cell Death
Anti-Cancer Agents in Medicinal Chemistry <sup>68</sup>Ga-labeled HBED-CC Variant of uPAR Targeting Peptide AE105 Compared with <sup>68</sup>Ga-NODAGA-AE105
Anti-Cancer Agents in Medicinal Chemistry Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids
Mini-Reviews in Medicinal Chemistry Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Editorial (Thematic Selection: Mitochondrial Dysfunction & Neurological Disorders)
Current Neuropharmacology A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity
Current Genomics